VJHemOnc is committed to improving our service to you

ASH 2019 | Transcend NHL 001: liso-cel in R/R B-cell NHL

VJHemOnc is committed to improving our service to you

David Maloney

David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, outlines the results of the Transcend NHL 001 study (NCT02631044). This is a phase I study in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) receiving lisocabtagene maraleucel, an investigational, anti-CD19, defined composition, 4-1BB, CAR T-cell product administered at a target dose of CD4+ and CD8+ CAR T-cells. Dr Maloney talks about the use of this CAR-T product in the outpatient setting, the future perspectives for this agent and patient-reported outcomes. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter